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Neuronal nitric oxide synthase is widely regarded as an important contributor to a
number of disorders of excitable tissues. Recently the adaptor protein NOS1AP has
emerged as a contributor to several nNOS-linked conditions. As a consequence,
the unexpectedly complex mechanisms of interaction between nNOS and its effector
NOS1AP have become a particularly interesting topic from the point of view of both
basic research and the potential for therapeutic applications. Here we demonstrate
that the concerted action of two previously described motif regions contributing to the
interaction of nNOS with NOS1AP, the ExF region and the PDZ ligand motif, efficiently
excludes an alternate ligand from the nNOS-PDZ ligand-binding pocket. Moreover, we
identify an additional element with a denaturable structure that contributes to interaction
of NOS1AP with nNOS. Denaturation does not affect the functions of the individual
motifs and results in a relatively mild drop, ∼3-fold, of overall binding affinity of the
C-terminal region of NOS1AP for nNOS. However, denaturation selectively prevents the
concerted action of the two motifs that normally results in efficient occlusion of the PDZ
ligand-binding pocket, and results in 30-fold reduction of competition between NOS1AP
and an alternate PDZ ligand.
Keywords: nos1ap, nNOS, PDZ domain, fluorescence polarization, dissociation constant, molecular dynamics
simulation, multi-site binding, ZLc-002-1
INTRODUCTION
NMDA receptor mediated signaling through nNOS is increasingly recognized as a contributor
to a number of neurological conditions including stroke, depression and neuropathic pain
(Florio et al., 2009; Hill et al., 2012; Doucet et al., 2013; Lee et al., 2015). Experimental models
suggest that NOS1AP may mediate the actions of NMDA-driven nNOS function for example in
excitotoxic conditions such as neonatal hypoxia and anxiety induced by chronic mild stress (Li
et al., 2013; Zhu et al., 2014). It has been specifically suggested that nNOS-NOS1AP interaction
could be a therapeutic target in schizophrenia (Weber et al., 2014; Freudenberg et al., 2015),
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while NOS1AP has emerged as a highly significant associated
gene in cardiovascular conditions (Arking et al., 2006; Kapoor
et al., 2014). For these reasons the interaction between nNOS and
NOS1AP is emerging as a potential target for drug development.
Both peptide and small molecule inhibitors of the interaction
have already been reported (Li et al., 2013, 2015; Zhu et al., 2014),
and improved understanding of the interaction between nNOS
and NOS1AP may assist in future drug development.
The interaction had originally been considered to be a
canonical PDZ interaction (Jaffrey et al., 1998; discussed in
Courtney et al., 2014), which involves the C-terminal 7–9 residues
of a ligand (NOS1AP in this case) docking into a well-defined
pocket in a PDZ domain (between residues 14–98 of nNOS
in this case, Tochio et al., 1999). Supporting this, deletion of
the C-terminus of NOS1AP eliminates binding to nNOS by
conventional pulldown or immunoprecipitation methods (Jaffrey
et al., 1998; Li et al., 2015; Candemir et al., 2016). Conflicting
with this, is that the last 9–20 residues of NOS1AP are not
sufficient for interaction to be detected by either pulldown or
immunoprecipitation methods (Li et al., 2015; Candemir et al.,
2016). The explanation for this finding is that the C-terminal PDZ
ligand motif alone has exceedingly low affinity for nNOS (Li et al.,
2015) but it nevertheless contributes stabilization to a primary
interaction with an internal NOS1AP sequence containing an
ExF motif. This results in ∼5-fold increased affinity and a ∼5-
fold slower off-rate and, in the context of multiple wash steps
of a conventional pulldown assay this amounts to the difference
between strong binding and no binding (Li et al., 2015).
Thus the concerted action of these two interaction sites
leads to a longer-lived protein complex and this appears to be
important for the efficiency of mediation of signal transduction
pathways, specifically the activation of the p38 pathway and
excitotoxic neuronal cell death (Li et al., 2015). Nevertheless, it
has not been shown whether docking of NOS1AP to nNOS via
the ExF motif alone has any influence on the competence of the
nNOS PDZ pocket to bind ligands, nor even the apparent affinity
with which NOS1AP occupies the actual PDZ ligand-binding
pocket when NOS1AP is bound to nNOS. The independence
and interdependence of the two nNOS-interacting motifs has not
been directly addressed.
Here we report that denaturation of the C-terminal nNOS-
binding region (which contains both the ExF motif and the PDZ
ligand) does not prevent interaction via the ExF motif, suggesting
the latter does not require a structure that can be denatured.
Surprisingly, however, we find the denatured binding region
interacts with nNOS N-terminus at a similar affinity whether
or not the PDZ ligand is present, in sharp contrast to previous
findings using the native binding region (Li et al., 2015) in which
ExF and PDZ ligand regions cooperate to generate high-affinity
stable binding of nNOS. As a result, the reported increase in
affinity of the C-terminal NOS1AP region containing both nNOS
binding motifs is largely lost in the denatured peptide. This
suggests PDZ pocket occupancy depends on a native structure.
Indeed we show directly that, whereas the two-site binding region
of NOS1AP (residues 400–506, human numbering) in native
form exhibits high affinity competition against exogenous ligands
for the nNOS PDZ-binding pocket (∼0.8 µM), denaturation
of this NOS1AP fragment reduces competition at the pocket
30-fold. This shows that a relatively small change in overall
affinity of the two-site binding region, NOS1AP[400–506], can
mask a considerable drop in binding of one of the sites, and
demonstrates the importance of investigating interactions at each
site independently where feasible. The PDZ-binding C-terminal
ligand of NOS1AP is a short peptide, and a molecular dynamic
simulation suggest that no rigid structure is required for docking
of the PDZ ligand to nNOS, which appears to only involve the
last 3–4 amino acids. However, secondary structure prediction
algorithms reveal potential structural elements that form between
the ExF motif region and the PDZ ligand. Our data is consistent
with a requirement for a structural element outside the ExF
and PDZ motifs to be in a native conformation to allow
concerted action of the ExF motif and PDZ ligand interactions. In
denatured state, even if the two interaction sites can bind nNOS
independently of one another, they cannot cooperate with one
another to generate the increased apparent affinity of interaction
otherwise seen, and this is most likely for steric reasons. The
potential relevance of this additional requirement for nNOS-
NOS1AP to the development of inhibitory strategies is discussed.
MATERIALS AND METHODS
Peptides
Peptide “GDLV” refers to NH2-RRRRWGDLV-COOH, whereas
F-GDLV refers to the N-terminally fluoresceinated variant. Both
were obtained from Genic Bio (Shanghai, China) and were of>92
and >97% purity respectively. Peptide “EIAV” refers to NH2-
DSLDDEIAV-COOH, corresponding to the last 9 amino acids of
rat/mouse NOS1AP, was synthesized as described Li et al. (2013)
by Xigen AG (Lausanne, Switzerland). The corresponding human
sequence is NH2-DGLDDEIAV-COOH, i.e., a S>G substitution
at position−7 from the C-terminal valine. We previously aligned
the C-terminal region from multiple species (Li et al., 2015)
which showed that birds, reptiles and terrestrial and marine
mammals typically have a serine at this position, fish typically
have a cysteine, while the primates we aligned have a glycine.
As we do not find evidence for the contribution of the residues
distal to the C-terminus to binding, and this sequence alone binds
nNOS extremely weakly (Li et al., 2015), serine does not appear
to contribute to binding. As glycine has no side chain (only two
hydrogens on the alpha-carbon), its contribution to binding is
unlikely to be greater than serine. Notably, rat, mouse and human
nNOS-PDZ domains are identical in the region from residues 6–
126 except for D/G substitution at amino acid 69. This residue
is not close to the PDZ-ligand binding pocket and faces solvent
in solved structures 1B8Q (Tochio et al., 1999) and 1QAV/1QAU
(Hillier et al., 1999).
Antibodies
Antibody against NOS1AP (rabbit polyclonal, R-300, sc-9138,
RRID:AB_2251417) was from Santa Cruz Biotech, and Dy-
Light coupled secondary antibody was from Cell Signaling
Technologies.
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Plasmid constructs
pET28a-TAT-NOS1AP[400–506], pET28a-TAT-NOS1AP[400–
503], pET28a-TAT-NOS1AP[400–503] E429A, pET28a-TAT-
NOS1AP[400–503] F431A, pET28a-nNOS[1–155], pGEX-nN
OS[1–155], pGEX-6P-NOS1AP[400–503], pGEX-6P-NOS1AP
[400–506], pGEX-6P-NOS1AP[432–506], pGEX-6P-NOS1AP
[400–503] F431A and pGEX-6P-NOS1AP[400–506] F431A,
encoding human protein sequences (amino acids as specified)
fused to GST, His and His-TAT tags, and pGEX-HRV3C protease
expression vector were previously described Li et al. (2015).
Recombinant Protein Expression and
Purification
His-TAT-NOS1AP fusions were purified under native conditions
using lysozyme-based lysis conditions (Courtney and Coffey,
1999) or under denaturing conditions as described Becker-Hapak
et al. (2001). His-nNOS(1–155) was generated as described
Li et al. (2015) as was GST-nNOS(1–155) and GST. All His-
nNOS[1–155] used for fluorescence polarization (FP) assays
was polished by Superdex200 size-exclusion chromatography as
described Li et al. (2015). NOS1AP[400–506], NOS1AP[400–
503], NOS1AP[432–503] and NOS1AP[400–506] F431A were
obtained from GST fused versions by on-column cleavage using
GST-HRV3C protease as described Li et al. (2015).
Solid-Phase No-Wash Binding Assay
This was carried out as previously described Li et al. (2015).
Briefly, 5 µl beads bound to 1 µg GST-fused nNOS protein
(or GST for background measurement) were rotated with
concentrations of recombinant His-TAT-NOS1AP peptides as
shown for 1 h at 4◦C and transferred to multiscreen filter plates
(Millipore). Unbound peptides were removed by centrifugation,
beads were resuspended in LSB (Cao et al., 2005) and protein
eluted with Laemmli buffer. The affinity of each peptide was
determined using fluorescent immunoblotting quantified with
the Odyssey infrared imaging system (LI-COR) and ImageJ as
follows. Bound peptide, together with the background binding
of each TAT peptide to GST beads, was quantified in each blot
using a set of standard concentrations of the same TAT fragment
on the same blot. Background binding to GST, barely detected
except at the highest fragment concentration, was subtracted in
each case. Fitting was performed for each replicate with Excel
using the quadratic solution formula to account for bound ligand,




FP assays were carried using a BMG Polarstar OPTIMA reader
as previously described Li et al. (2015). Briefly, synthetic peptide
corresponding to the optimal nonamer ligand for the PDZ
ligand-binding pocket of nNOS, based on the peptide scan
of Stricker et al. (1997), was labeled with fluorescein at the
N-terminus and used as a fluorescent ligand. This is referred
to as F-GDLV. Fluorescence titration was performed by adding
increasing amounts of His-tagged nNOS(1–155) to a constant
amount of the fluoresceinated peptide (1 µM) in FP buffer
(50 mM Tris buffer, pH 7.4, containing 100 mM NaCl, 1 mM
EDTA, 0.1% BSA). The dissociation constant (Kd) was obtained
by fitting the titration curves with the classical one-site binding
model with MS Excel Solver the quadratic solution formula to
account for bound ligand, as shown above in the section “solid-
phase no wash assay.” The Kd values were obtained in triplicate
from each of two different batches of His-nNOS, curve fitting
was performed on each replicate. The mean ± SEM shown in
Figure 2 and Table 2 (10.7 ± 0.8 µM) corresponds to the results
of curve fittings to the 6 replicates. The individual nNOS batches
gave values of 10.2± 1.7 µM and 11.2± 0.2 µM.
Competition FP was carried out using 1 µM F-GDLV peptide
4 µM His-nNOS(1–155) and increasing amounts of competitor
peptide as indicated. Approximate values for Kc, the dissociation
constant of the competitor, were obtained using the formula
for single site competition as described in Harris et al. (2001).
For each experiment the data were fitted with MS Excel Solver
according to the measured dissociation constant for the specific
nNOS batch used in the experiment (see above).
Molecular Dynamics Simulation
All simulations were carried out using the Desmond Molecular
Dynamics System v2.2 (D. E. Shaw Research, New York, NY,
USA) and Schrodinger suite tools (Schrodinger, LLC, Portland,
OR, USA) on the supercomputing clusters of the Centre for
Scientific Computing (Espoo, Finland). NMR structures (pdb
ID 1B8Q) were imported using Schrodinger’s Maestro to assign
proper bond orders. Next, the structures were prepared using
Schrodinger’s Protein Preparation Wizard, following a standard
solvation box with 10 Å buffering, 150 mM Na+ and Cl− ion
buffering, and SPC water model. The OPLS-AA/2005 force field
was used for all simulations with a multi-step minimization
procedure using default settings to relax the system prior to
simulation. For the molecular dynamics production runs, the
NPT ensemble was used and a trajectory for 10 ns generated
and visualized using the Maestro Trajectory Player. Three poses
are shown at 0.15 ns intervals to show the rapid movement
of the non-docked ligand residues compared with the docked
ones.
RESULTS
We previously demonstrated that it is possible to use the ExF
site-bearing peptides alone as neuroprotectants in models
of excitotoxic neuronal stress. This was achieved using
recombinantly expressed and purified TAT-fused peptides
that pass the plasma membrane (Li et al., 2015). In this previous
report, we found using a quantitative solid-phase binding assay
that TAT-fused peptides of NOS1AP (incorporating residues
from 400 onward, human usage) exhibited ∼5-fold lower
affinity when the PDZ ligand (residues 504–506) was lacking
(Table 1, column 1; Li et al., 2015). This was consistent with
a ∼5-fold lowering of the off-rate of interaction of the nNOS-
NOS1AP complex when the PDZ ligand motif was present that
we observed using an independent assay system. Additional
Frontiers in Molecular Neuroscience | www.frontiersin.org 3 March 2017 | Volume 10 | Article 58
fnmol-10-00058 March 13, 2017 Time: 16:51 # 4
Li et al. Occlusion of the nNOS-PDZ Pocket by NOS1AP
TABLE 1 | Comparison of Kd values for native and denatured forms of
NOS1AP for nNOS[1–155] previously reported and shown here.
N0S1AP residues Native (Li et al., 2015) Denatured (Figure 1)
400–506 0.75 ± 0.1 µM 2.4 ± 0.3 µM
400–503 5.8 ± 1.0 µM 5.3 ± 0.9 µM
400–503 E429A 1.1 ± 0.3 mM 99 ± 19 µM
400–503 F431A 1.1 ± 0.2 mM 100 ± 20 µM
Affinity constants were obtained by fitting each replicate for each peptide.
Means ± SEM Kd values are indicated. Native His-TAT protein data is taken from Li
et al., 2015 whereas the denatured protein data carried out in parallel is shown here
in Figure 1. Note that denaturation selectively reduces the affinity of NOS1AP[400–
506]∼3-fold. The increased affinity of the essentially non-binding ExF point mutants
lacking of PDZ ligand is an expected consequence of denaturation, but these
proteins still have very low affinity for nNOS and this effect is unlikely to influence
the specific binding of NOS1AP fragments with functional ExF motifs.
quantitative and qualitative protein interactions supported this
interpretation and suggested that the PDZ motif, while having
little affinity itself, nevertheless contributed to the formation of a
stable interaction of nNOS with NOS1AP (Li et al., 2015).
A Native Conformation of NOS1AP Is
Required for the Concerted Action of the
PDZ Ligand and ExF Motif Region in
Binding nNOS
It is now well established that regions of proteins, domains of
proteins and even entire proteins can exist in natively unfolded
or intrinsically unstructured states (called IDP or intrinsically
disordered proteins; for review see Latysheva et al., 2015; Wright
and Dyson, 2015). It is thought that this allows these proteins
to adopt confirmations required for target-binding without
imposing such conformational constraints in the absence of
binding, thereby permitting the binding to different targets.
These regions and proteins are resistant to denaturation. In
contrast, other regions or often entire proteins are structured.
In this case, they form specific structures, and these are
denaturable by heat, chemical denaturants or other conditions
to which the proteins are not adapted. Thus, the comparison of
protein function before and after denaturation is an investigative
approach that can be used to determine the importance of
structural elements for the specific functions of a protein. This
does not necessarily mean that denaturation or loss of structure
(or the opposite) is a physiological mechanism of regulation,
although in some cases this is case (reviewed in Mitrea and
Kriwacki, 2013; Csizmok et al., 2016). The light-induced switch
of the J-alpha sequence of plant photoprotein Lov2 domains
from alpha-helical to unfolded state (Harper et al., 2003) is
one prominent example, which has been exploited by synthetic
biologists to generate optogenetic regulators of cell signaling
(Strickland et al., 2008; Wu et al., 2009; Lungu et al., 2012;
Melero-Fernandez de Mera et al., 2013, 2017; Guntas et al., 2015).
We previously reported two-site affinity measurements for
NOS1AP-nNOS interaction using TAT-fused NOS1AP protein
expressed and isolated from bacterial expression systems under
native conditions (Li et al., 2015). Uptake of recombinant
TAT-fusions into cells is promoted by denaturation and they
are presumed to be refolded in the cytoplasm by intracellular
chaperone systems (Becker-Hapak et al., 2001). Considering
the prevalence of functional intrinsically disordered regions
in the proteome and the lack of a predicted structured
domain in the C-terminal region of NOS1AP, we decided to
measure affinities of the denatured TAT-proteins in parallel
with the native versions, for the same sites using the same
no-wash pulldown assay as we previously used for the native
proteins (Li et al., 2015). We intentionally used a no-wash
pulldown assay in this study because we previously reported
that the conventional washing steps, which have no physiological
counterpart, greatly exaggerate the impact of PDZ motif on
overall binding affinity (Li et al., 2015). Figure 1 shows that
the affinity of nNOS for denatured NOS1AP[400–503], the
NOS1AP form that lacks the PDZ ligand motif, is similar to
that of the native protein (Li et al., 2015; Table 1). However, in
contrast to the results obtained with native protein, the affinity
difference between NOS1AP[400–506] and NOS1AP[400–503]
was almost completely lost, both having a similar affinity to that
previously described for native NOS1AP[400–503] (Table 1).
This suggests that, although the interaction of the internal ExF
motif region (present in NOS1AP[400–503]) with nNOS does not
require a pre-existing natively folded conformation, the increased
affinity obtained by concerted action of the two interaction
motifs in NOS1AP[400–506], in contrast does require a native
structure.
Fluorescence Polarization Can Be Used
to Directly Probe the Occupancy of the
PDZ Ligand-Binding Pocket of nNOS
This sensitivity of concerted NOS1AP binding to nNOS to
denaturation has considerable potential impact on the ability of
NOS1AP to compete with ligands for the nNOS PDZ pocket.
To investigate this in more detail, we set up a solution-phase
FP competition assay to selectively monitor the occupancy of
the nNOS-PDZ ligand pocket independent of overall protein
interaction, by use of a fluorescent ligand of the pocket
(Figure 2A). Based on a previously published random peptide
screen (Stricker et al., 1997) we developed the 9 amino acid
FP ligand fluorescein-RRRRWGDLV, termed here ‘GDLV.’ This
interacts with nNOS[1–155] with an affinity 10.7 ± 0.8 µM
(Figure 2B), and unlabelled GDLV competes with a comparable
affinity (10.7 ± 2.0 µM, Figure 2C). This is in sharp contrast to
the C-terminal 9 amino acid PDZ ligand motif from NOS1AP,
DSLDDEIAV, which was reported to have extremely low affinity
(>600 µM in fluoresceinated form, Li et al., 2015; Table 2).
Consistent with this, we cannot detect any competition for
F-GDLV/nNOS[1–155] interaction by up to 300 µM unlabelled
NOS1AP-9C peptide (“EIAV,” Figure 2D).
The nNOS-NOS1AP Interaction Inhibitor
ZLc-002-1 Shows Weak Affinity for the
nNOS PDZ Ligand-Binding Pocket
Recently N-(2-carboxyacetyl)-D-valine-methyl ester, also known
as ZLc-002-1, a valine-based analog of the C-terminus of
NOS1AP (Figure 3A), has been proposed as a competitive
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FIGURE 1 | A native conformation of NOS1AP is required for the concerted action of the PDZ ligand and ExF motif region on binding nNOS in a solid
phase no-wash binding assay. (A) Scheme depicting the no-wash solid-phase binding assay used to measure the interaction of NOS1AP peptides with nNOS.
(B) Representative fluorescent immunoblot images showing binding of His-TAT-NOS1AP to GST (background binding, left lanes, hardly visible) and
GST-nNOS[1–155] (right lanes) at concentrations of protein indicated. Bound peptide was detected by NOS1AP primary antibody and an Odyssey infrared imaging
system. (C) Curves of specific NOS1AP binding, after correcting for background and normalizing to internal standards on each gel for each protein, from replicates
of experiments shown in (B). Data are mean ± SEM (n = 3) and superposed curves were fitted to data according to a 1-site model as described in Section
“Materials and Methods.”
FIGURE 2 | Fluorescent peptide FITC-RRRRWGDLV can be used as a fluorescence polarization ligand to directly probe the occupancy of the PDZ
ligand-binding pocket of nNOS. (A) Scheme depicting the competition fluorescence polarization (FP) assay. Optimal peptide ligand RRRRWGDLV (shown as gray
oval) was N-terminally fluoresceinated and used as an FP probe with acceptable dynamic range and affinity. The PDZ ligand binding pocket of nNOS (Tochio et al.,
1999, here shown in brown with two distinct binding sites) can bind to the FP probe (upper right panel) or the IAV motif of NOS1AP which also docks via ExF motif to
a second site on nNOS (lower right panel, Li et al., 2015). Thus competition FP reveals binding of peptides such as NOS1AP to the PDZ pocket and its possible
facilitation by additional sites such as the ExF motif. We indicate the ExF motif schematically as a β-sheet as secondary structure prediction algorithms suggest it may
form this motif (Li et al., 2015) even though our results here suggest the function of this region is resistant to denaturation (Figure 1). (B) Increasing His-nNOS[1–155]
in the presence of F-GDLV ligand (1 µM) reveals FP data fitting a single-site binding curve, based on the free concentration of ligand. A representative curve is shown
(n = 3), and mean of experiments with two different nNOS batches gave a Kd of 10.7 ± 0.8 µM (mean ± SEM, using n = 6 curve fittings). (C) Unlabelled GDLV
peptide competes with F-GDLV (1 µM) for binding His-nNOS[1–155] (4 µM) resulting in a competition curve indicating a Kc (affinity of competitor) of 10.7 ± 2.0 µM
(datapoints shown are mean ± SEM, n = 3), consistent with the F-GDLV-nNOS binding data in (B). (D) Unlabelled EIAV peptide (the last nine amino acids of
NOS1AP, DSLDDEIAV) shows no competition with F-GDLV (1 µM), with no detectable displacement at up to 300 µM (datapoints shown are mean ± SEM, n = 3).
inhibitor for nNOS PDZ pocket ligands and has shown efficacy
against anxiety induced by chronic mild stress (Zhu et al.,
2014). However, no actual binding or competition data has
been reported for this molecule. Using the FP competition
assay we find that ZLc-002-1 does compete with the PDZ
pocket ligand F-GDLV (Figure 3B). The affinity is rather weak
(>100 µM, Kc, which represents the dissociation constant of the
competitor, i.e., ZLc-002-1 in this case), but it should be noted
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TABLE 2 | Comparison of Kd values for binding of NOS1AP forms to nNOS[1–155] and Kc values for competing with F-GDLV ligand as measured by
fluorescence polarization (FP).
Protein or peptide Kd (overall affinity for binding
nNOS[l–155] at any site(s))
Kc (affinity for nNOS-PDZ pocket, by
competition fluorescence polarization)
RRRRWGDLV (synthetic) 10.7 ± 0.8 µM (FP, Figure 2B) 10.7 ± 2.0 µm (Figure 2C)
DSLDDEIAV (NOS1AP-9C) >600 µM (FP, Li et al., 2015) >>300 µM (Figure 2D)
NOS1AP 400-506 His-TAT fusion Native 0.75 ± 0.1 µM (PD, Li et al., 2015) 0.83 ± 0.3 µM (Figure 5A)
Denatured 2.4 ± 0.3 µM (PD, Figures 1B,C) 24 ± 2 µM (Figure 5B)
NOS1AP 400-503 His-TAT fusion Native 5.8 ± 1.0 µM (PD, Li et al., 2015) n.d.
Denatured 5.3 ± 0.9 µM (PD, Figures 1B,C) n.d.
NOS1AP 400–506 cleaved from GST 0.05 µM (Li et al., 2015) 0.52 ± 0.21 µM (Figure 4B)
N0S1AP 400–503 cleaved from GST n.d. >>10 µM (Figure 4C)
NOS1AP 400–506 F431A cleaved from GST n.d. >>10 µM (Figure 4D)
NOS1AP 400–503 F431A cleaved from GST n.d. >>10 µM (Figure 4E)
NOS1AP 432–506 cleaved from GST n.d. >>10 µM (Figure 4F)
Means ± SEM are indicated. “n.d.”, several proteins cleaved from GST fusion were not measured by a comparable assay and therefore there are no Kd estimates in
these cases. However by more qualitative assays NOS1AP[400-506]E429A, F431A and NOS1AP[432-506] exhibit no or reduced interaction with nNOS[1-155] (Li et al.,
2015).
FIGURE 3 | ZLc-002-1, a prodrug-derived analog of the C-terminal PDZ ligand motif of NOS1AP, shows weak affinity for the nNOS PDZ
ligand-binding pocket. (A) (i) The structure of ZLc-002-1 [N-(2-carboxyacetyl)-D-valine-methyl ester], reported to be the active metabolite of the pro-drug ZLc-002
[N-(2-carbomethoxyacetyl)-D-valine-methyl ester], is shown. (ii) For direct structural comparison, the C-terminus of NOS1AP (Ala505-Val506 and preceding peptide
bond only) is shown. (B) Competition FP assay shows the ZLc-002-1 is able to compete with F-GDLV ligand with a Kc of 115 ± 29 µM (n = 14).
that this charged (and probably cell-impermeant) carboxylic
acid species is thought to be generated in cells exposed to the
cell-permeant ester prodrug ZL002 by cleavage with esterases.
Ester-loading is a well-known strategy used for decades for
example in loading calcium dyes into cells. In such cases,
incubation with 2.5 µM uncharged ester form has been reported
to lead to 200–800 µM cytoplasmic concentrations after 15 min
of exposure (Hagen et al., 2012). Our observed Kc for ZLc-
002-1 is therefore well within the intracellular concentration
range expected from the reported 72 h incubation with 10 µM
ester to obtain an effect in cell-based experiments (Zhu et al.,
2014).
The ExF Site of NOS1AP Is Required to
Compete With Docking of PDZ Ligand to
nNOS But Is Not Sufficient
In contrast to ZLc-002-1, native NOS1AP[400–506] which
contains two sites of interaction (Li et al., 2015), shows a much
higher affinity in this assay (0.52 ± 0.21 µM; Figure 4B).
NOS1AP[432–506] completely lacks the ExF motif and, like
the NOS1AP-9C peptide (Figure 2D), also fails to compete
(Figure 4D) even though the C-terminal PDZ ligand motif is
present. Native NOS1AP[400–503], which as a His-TAT fusion
binds nNOS almost as well as NOS1AP[400–506] in native state
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FIGURE 4 | Competition FP assay of PDZ domain pocket of nNOS shows, using purified NOS1AP sequences, that the ExF site is required to compete
with docking of PDZ ligand but not sufficient. (A) Schematic representation of different recombinant peptides cleaved and purified from GST used in this figure.
(B) Competition FP assay shows that NOS1AP[400–506], which contains both ExF region and PDZ ligand “IAV,” competes with the PDZ pocket ligand F-GLDV with
high apparent affinity (Kc = 0.52 ± 0.21 µM, n = 6). (C) Peptide NOS1AP[400–503] which binds nNOS with an affinity similar to NOS1AP[400–506] (Figure 1B and
Table 1; Li et al., 2015) does not detectably exclude the PDZ pocket ligand (n = 6); (D) Similarly NOS1AP[400–506] which does exclude the ligand (A), fails to do so
if the ExF site is deleted (here using NOS1AP[432-506]) (n = 6); (E,F) Mutational inactivation of the ExF motif (F431A mutation) in NOS1AP[400–506] (E) or
NOS1AP[400–503] is also sufficient to prevent any exclusion of PDZ ligand (F) (n = 6 each).
(Li et al., 2015) and equally well when denatured (Figure 1),
does not compete with PDZ ligand in this assay (Figure 4C).
This is the expected outcome if the ExF and PDZ ligand sites
are non-overlapping and independent, because 400–503 does not
have a PDZ ligand and should not be able to compete with the
PDZ probe F-GDLV. Finally, NOS1AP[400–506] F431A which
contains a PDZ ligand but bears an inactivated ExF motif, and
NOS1AP[400–503] F431A which has neither functional ExF nor
PDZ motif, each fail to compete in the FP assay (Figures 4E,F).
In conclusion, these data show the NOS1AP PDZ ligand motif
alone does not compete effectively at the PDZ ligand pocket,
and nor is the functional ExF region alone sufficient. But a
NOS1AP sequence containing both functional ExF region and
PDZ ligand together is able to occupy the PDZ ligand pocket.
This data is consistent with and provides more direct evidence
than previously available in support of an earlier model of the
nNOS-NOS1AP interaction (Figure 3Biii of Li et al., 2015).
The Native State of a Structural Element
in NOS1AP Greatly Increases the Affinity
for the PDZ Ligand Binding Pocket of
nNOS
We applied this FP competition assay to the native and denatured
His-TAT-fused NOS1AP[400–506] peptides that we had already
characterized by the solid phase assay (Figure 1; Li et al., 2015).
We find that native His-TAT- NOS1AP[400–506] competes
with F-GDLV, whereas denatured His-TAT-NOS1AP[400–506]
interaction is 30-fold weaker (Figures 5A,B; significant difference
at P < 0.0001, two-tailed unpaired t-test, n = 4). This difference
greatly exceeds the ∼3-fold impact of denaturation on overall
binding affinity by no-wash pulldown assay (Figure 1; Kd and
Kc data are compared in Table 2). In the competition-FP assay
we only monitor the state of the PDZ ligand pocket so this data
alone does not distinguish between denaturation destroying the
affinity of the ExF region or disrupting the concerted action of
the ExF region and PDZ motif. However, considering the protein-
interaction results shown in Figure 1 and Table 1 (also Li et al.,
2015), we can conclude that the interaction by the ExF region
is resistant to denaturation and it is the concerted action of the
two sites to occlude the pocket that fails upon denaturation.
Furthermore it is clear that the denaturation procedure used here
does not merely result in loss of functional protein by aggregation
as this would affect all binding events similarly but the data
shows a 30-fold effect on PDZ ligand occupancy and no effect
on nNOS binding the via ExF motif region (compare Kc for
NOS1AP[400–506] with and without denaturation and Kd for
NOS1AP[400–503] with and without denaturation, Table 2).
Molecular Dynamics Simulation of
nNOS-NOS1AP PDZ Ligand Interaction
Two possible explanations are that either the PDZ motif
itself is denaturable or that there is an additional denaturable
element required for facilitating the concerted action of the two
interaction sites. The term “denaturable” refers here to an element
the properties of which are lost after denaturation of its structure,
and excludes intrinsically disordered sequences. This does not
necessarily imply that denaturability is itself a functional property
that is modulated in vivo although in some cases this has been
demonstrated (Mitrea and Kriwacki, 2013; Csizmok et al., 2016).
Canonical C-terminal PDZ ligands are short peptides,
typically too short to have a stable structure, and are thus
considered to represent a class of intrinsically disordered regions
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FIGURE 5 | Competition FP assay shows that the native state of a structural element in NOS1AP greatly increases the affinity for the PDZ ligand
binding pocket of nNOS. (A) Native His-tagged TAT-NOS1AP[400–506], which shows affinity of 0.75 µM by solid-phase no-wash assay (Li et al., 2015; Table 1)
exhibits a Kc of 0.83 ± 0.30 µM for competition at the PDZ pocket, by competition FP with F-GDLV ligand (n = 4). (B) The same peptide prepared under standard
denaturing conditions (as in Figure 1), exhibits over 30–fold lower Kc (24 ± 2 µM), a 10-fold greater reduction compared with loss of overall protein-interaction
affinity seen in solid-phase assay (Figure 1), suggesting that the native structure required for concerted action of the ExF and PDZ ligand motifs is even more
important for NOS1AP to compete at the PDZ ligand binding pocket than for binding (n = 4).
(Ivarsson, 2012). The NOS1AP C-terminal PDZ ligand itself,
residues 504–506 and potentially those preceding it, is therefore
not by itself expected to form a stable structure. Any stable
structure it might adopt in free solution could lead to an energy
barrier impeding the acquisition of the bound state in the PDZ
ligand binding pocket. We wished to more precisely predict
how this might influence the interpretation of the binding data.
Therefore, we carried out a molecular dynamic simulation based
on the existing NMR structure for nNOS docked with the
melatonin receptor peptide (1B8Q.pdb). This process calculates
the positions of all atoms from a starting point after each of
a number of specified small time steps. This models a relevant
atomic-level representation of the binding event between the
peptide and protein in the predicted binding pocket and reveals
the biophysics of this binding event. This can provide support for
a specific hypothesis or it can contradict it. For example if the
simulation shows a candidate ligand leaves a binding pocket, the
binding event is predicted to be non-existent.
Comparing the docking of MelA peptide in the published
NMR structure (Tochio et al., 1999) and NOS1AP PDZ ligand
(Figure 6 and Supplementary Movie) reveals that interaction of
the peptides with the PDZ pocket is predominantly based on
backbone–backbone interactions rather than any specific rigid
conformation of side chains. Specifically, the hydrogen bond
interactions between the peptide and protein backbones are the
key driving force of the interaction rather than other forces, (i.e.,
hydrophobicity, van der Waals forces). The simulation (Figure 6
and Supplementary Movie) specifically shows that the last three
residues remain docked in the pocket whereas the remaining six
residues move rapidly over the protein on a picosecond timescale
and do not remain docked with any specific surface region of
nNOS. The results of the simulation are therefore consistent
with (i) a lack of requirement for a pre-formed structure of
the PDZ ligand motif for binding to the PDZ pocket and (ii)
a participation of only the 3 most C-terminal amino acids of
the ligand (isoleucine-alanine-valine) in the interaction with
nNOS.
We conclude that a pre-existing structure of the PDZ ligand
in NOS1AP is unlikely to be required. For these reasons the
disruption of the concerted action of the two binding sites by
denaturation of the NOS1AP C-terminal nNOS binding domain
cannot be ascribed to either motif alone - neither the internal ExF
motif, as it interacts even if denatured (Figure 1), nor the PDZ
ligand as it interacts without adopting a specific fold (Figure 6).
Secondary Structure Prediction of the
C-Terminal nNOS Binding Region of
NOS1AP
We have found that denaturation does not affect the affinity of
the ExF-containing region of NOS1AP for nNOS (residues 400–
503, Table 1). MD simulation suggests the C-terminal PDZ motif
interaction involves only 3 amino acids (Figure 6), which is too
short to be sensitive to denaturation. Therefore, the denaturation-
induced sharp decline in competition at the PDZ pocket (Figure 5
and Table 2) as well as the reduced interaction with nNOS
of denatured NOS1AP containing both these sites (residues
400–506, Table 1) indicates that denaturation targets a third,
previously unidentified, element in the C-terminal region of
NOS1AP (residues 400–506) that is required for optimal binding
to nNOS. We specifically infer a folded structural element most
likely residing between the ExF region and the PDZ ligand at
the extreme C-terminus. As the PDZ ligand of NOS1AP interacts
with the PDZ domain pocket and deletion of only three amino
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FIGURE 6 | Molecular dynamics simulation of nNOS-NOS1AP PDZ ligand interaction suggests only the last three C-terminal residues of NOS1AP
reside in the ligand binding pocket. Three frames at 0.15 ns intervals are shown from a molecular dynamics simulation of the NOS1AP C-terminus (last nine
amino acids, C-alpha chain is represented as a white line) docked in the PDZ pocket of the nNOS-extended PDZ domain. Note one end (C-terminal valine indicated
with thin red arrow) remains close the PDZ-β2 (orange), while the N-terminal end (N-terminal indicated with thin cyan arrow) moves rapidly in the nearby space but is
not positioned over any one surface. The simulation (full 10 ns movie file in the Supplementary Movie) suggests only the 3 C-terminal residues within the 9-mer ligand
form stable interactions during this simulation.
acids from the C-terminus of NOS1AP eliminates occlusion
of the PDZ ligand binding pocket (Figure 4C), the ExF motif
region must interact at another site on the compact nNOS
N-terminal domain. The concerted simultaneous binding of both
sites to the nNOS domain must impose steric requirements
on their relative orientations, as was previously demonstrated
for efficient binding of dimeric ligands to the tandem PDZ
domains of PSD95-PDZ1-2 (Long et al., 2003). In the case
of nNOS-NOS1AP interaction it seems likely that the steric
requirements could be fulfilled by the inferred folded structural
element of NOS1AP. To explore the possible presence of folded
elements, we applied secondary structure prediction methods
to the C-terminal nNOS binding region, i.e., NOS1AP residues
400–506 (Figure 7A).
The JPRED3 engine (Cole et al., 2008) predicts two main
structural elements within the C-terminal nNOS binding region.
The first is a β-sheet region around the ExF motif, from
residues 425 to 432. The requirements for residues 429 and
431 but not 430 is consistent with a beta sheet structure
bearing residues with alternating orientations, but the equal
affinities of denatured 400–503 and 400–506 (Figure 1) suggests
the ExF motif readily adopts a binding conformation even
after denaturing conditions. The second structural element is a
putative α-helix from 452 to 460, with a third predicted, again
α-helical, around residues 484–489. These putative helical regions
may potentially represent a denaturable element that could serve
a role in orientation of ExF and PDZ ligand motifs and conversely
denaturing them might then lead to steric incompatibility of the
two sites to bind a single nNOS molecule, which is what we
observe.
DISCUSSION
Our data show that not only are two binding elements, the
ExF motif and PDZ ligand required for the optimal binding
of NOS1AP to nNOS as described before (Li et al., 2015),
but that there is in addition a requirement for a denaturable
structural element for the concerted action of these two sites
(Figures 7Bi,ii). This is presumably important to provide
appropriate steric conditions for the two sites to simultaneously
access their respective binding sites on nNOS. Although it was
previously shown (Li et al., 2015; and shown again here in
Figures 1, 4, 5) that the NOS1AP C-terminal PDZ ligand motif
was dispensable for binding of NOS1AP to nNOS – the ExF motif
region was sufficient for binding – it was not previously clear
whether or not the ExF-interaction also occluded the PDZ motif
site of the bound nNOS molecule by either steric or allosteric
mechanisms, or left it vacant and able to interact. Here we
have demonstrated directly that the interaction of NOS1AP to
nNOS via the ExF motif region and PDZ ligand interaction are
separable events, and thus binding of nNOS by NOS1AP[400–
503] via the ExF motif alone has no detectable occluding effect
on the PDZ pocket which remains equally able to bind ligand
(shown schematically in Figure 7Biii; corresponding data in
Figure 4C).
Conversely, we provide here an estimate of the apparent
competitor affinity at the PDZ ligand binding pocket by a NOS1AP
sequence containing the C-terminal PDZ ligand motif. The latter
motif of NOS1AP in isolation is known to have extremely weak
affinity for nNOS (Figure 2; Li et al., 2015; Table 2). It is
also known that the presence of this ligand together with the
ExF motif within the C-terminal 107 amino acids of NOS1AP,
(i.e., residues 400–506) generates a high affinity interaction
with nNOS as previously described (Li et al., 2015) but this
does not mean the PDZ pocket would be occupied with the
same apparent affinity as the overall dissociation constant for
the NOS1AP-nNOS complex. We show directly that the two
motifs together lead to a high affinity occupancy of the PDZ
ligand binding pocket (apparent Kc ∼0.5 µM, Figure 4B) that
efficiently competes with an alternate model ligand (F-GDLV).
It is this efficient competition at the pocket that requires three
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FIGURE 7 | Proposed interplay between different regions of NOS1AP on interact with the N-terminal region of nNOS. (A) Secondary structure prediction
applied to the C-terminal region of NOS1AP (the human sequence is shown). The prediction shown here generated by the JPRED3 engine aligns multiple prediction
algorithms – the Jnet secondary structure prediction and residue burial prediction (0, 5, and 25% exposure to solvent for Jnet_0, _5 and _25), HMMER hidden
markov model profile-based prediction (jhhm) and PSI-BLAST position-specific scoring matrix prediction (jpssm) as well as Lupas coil predictions at window sizes
14, 21, and 28 as indicated (“-“ for each residue indicates less than 50% probability). Jnet Rel indicates reliability of prediction from 0 (lowest) to 9 (highest).
Consensus predictions indicate three regions of secondary structure and residue burial around (i) a predicted β-sheet region in the vicinity of the previously described
ExF motif, (ii) a helix prediction between residues 452-460 and (iii) a predicted α-helix from residues 484–489. (B) Schematic representation of the interaction of
different states of the C-terminal nNOS binding region of NOS1AP with the N-terminal PDZ-domain containing region of nNOS, indicating the state of occlusion of
the PDZ ligand-binding pocket in each case. (i) Native NOS1AP 400–506 interacts via the ExF site with nNOS, and via the C-terminal IAV motif with the PDZ ligand
binding pocket of nNOS as shown in the simulation of Figure 6. This is sterically possible and/or favored because of an intervening possibly α-helical structure
positioning both motifs appropriately, and the pocket is occupied, excluding other ligands (such as F-GDLV in the FP assays); (ii) Denatured NOS1AP 400–506 loses
the putative α-helical structure, can still interact via the ExF motif region, but the IAV sequence alone has too low an affinity and is not able to interact with nNOS at
the same time as the ExF motif as a result of the loss of intervening structure. The pocket is free to bind other ligands; (iii) NOS1AP 400–503 similarly can interact
with nNOS via the ExF motif but has no IAV PDZ ligand. Thus, even though structural integrity of the intervening sequence may be preserved, overall interaction is
not enhanced by any C-terminal interaction and importantly, this sequence is therefore unable to compete with ligands interacting at the PDZ binding pocket. (iv)
Denaturation of NOS1AP 400–503, though it disrupts the structural integrity of the intervening sequence, has little consequence to interaction because the ExF motif
region is resistant to denaturation and no other region contributes when the IAV sequence is deleted. The pocket is free to bind other ligands.
components – the ExF motif, the C-terminal PDZ ligand and
native conformation of a denaturable element within residues
400-506 of NOS1AP (Figure 7Bi) - not the overall NOS1AP-
nNOS interaction for which the ExF motif site is sufficient
(e.g., Figure 7Biii). Thus, without a native structure, the ExF
motif-containing region still interacts with nNOS (Figure 1
and Table 1) but the contribution of the PDZ ligand, which
is believed to be critical for signaling (Li et al., 2013, 2015),
is lost (Figure 7Bii; cf. Figure 5B). The impact in terms of
competition at the PDZ pocket is similar to deletion of the
C-terminal PDZ ligand (Figures 7Biii,iv; cf. Figure 4C and
Table 2).
We previously reported that it is possible to pharmacologically
inhibit the cellular impact of nNOS-NOS1AP interaction using
a competing PDZ ligand (Li et al., 2013) and more recently
reported a complementary approach using the ExF motif
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bearing peptide devoid of PDZ ligand (Li et al., 2015). The
distinct third requirement for a structural component that we
report here, is potentially a source of additional inhibitors.
Structure-based drug design may not easily target this element,
particularly in the complete absence of structural coordinates
of the molecule. The precise location of the third element
is not known, but it is likely to reside between ExF motif
(residues 429–431) and PDZ ligand (residues 504–506). The
predicted alpha-helical regions between residues 452–460 and/or
484–489 are therefore potential candidates. Even while the
structure of NOS1AP remains unsolved, the contributions of
these two candidate regions could nevertheless be evaluated
by mutational approaches. However, even without actually
locating the residues making up this denaturable element, future
library screens could reveal HTS hits that act at this site.
It is not uncommon for the actual binding sites of HTS-
derived protein–protein interaction inhibitors to be unclear.
For example, IC87201 inhibits the interaction of nNOS with
PSD95 and it is believed to interact with nNOS (Florio
et al., 2009) but that actual site of interaction of the nNOS
molecule has not been mapped. A similar molecule, ZL006,
was in fact described as having been designed precisely to
disrupt the interaction between two secondary structure elements
(Lai and Wang, 2010; Zhou et al., 2010), though once again
the actual interaction site has yet to be determined (Bach
et al., 2015). Therefore, it is important to identify the precise
requirements for protein–protein interaction, not only for the
design of new inhibitor molecules but also to interpret and
fully understand the mechanism of inhibition by HTS hits so
that their properties can be rationally explained and hits can
be optimized. For instance, a screen for modulators targeting
the denaturable element we have reported here would most
easily be addressed using an assay that reports its function, i.e.,
allowing the concerted action of PDZ ligand and ExF motif for
interaction of NOS1AP binding to nNOS. Such a screen would
therefore inevitably also report inhibitors of both the PDZ ligand
interaction and the ExF motif interaction. The actual site of
action of screen hits would therefore have to be deconvolved
by additional site-specific assays once screen hits have been
revealed and the knowledge that three distinct elements are
involved in the interaction is required to successfully achieve
this.
We previously demonstrated that the PDZ ligand contributes
an increased stability of the interacting complex and that
competition at the PDZ ligand site alone inhibits signaling,
presumably due to a reduced lifetime of this complex impacting
on NMDA receptor/nNOS-dependent signaling outputs. The
additive impact of the PDZ ligand on affinity is shown
here to be largely lost after denaturation. This suggests that
any successful targeting of the novel denaturable structural
element revealed in this report would likely reduce the
affinity of NOS1AP for nNOS and lifetime of the nNOS-
NOS1AP complex in a manner similar to that we have
observed by competition at the PDZ ligand-binding site
(Li et al., 2015). Structural elements in proteins are not
completely rigid and there is no evidence that the C-terminal
region of NOS1AP acts like a highly stable globular protein.
Therefore, it is reasonable to expect that the required structural
element has sufficient dynamic ‘breathing’ movement to
allow its targeting by small molecules in analogous way
to that proposed for ZL006 (Lai and Wang, 2010; Zhou
et al., 2010). Moreover, given the requirement for this
element for optimal interaction of NOS1AP with nNOS
and for occlusion of the PDZ ligand-binding pocket, any
dynamic reorganization of this element could potentially
form the basis of additional cellular regulation of nNOS-
NOS1AP interaction. However, such cellular regulation is
speculative as there is currently no evidence to support
an endogenous regulation of this element at this time.
Nevertheless, it should be noted that NOS1AP is not the
only protein reported to interact with the PDZ ligand-
binding pocket of nNOS. Other candidates for interaction at
this site include phosphofructokinase-M (Firestein and Bredt,
1999), the melatonin A receptor (MelA, Tochio et al., 1999),
alpha-adrenergic receptors (Pupo and Minneman, 2002), the
transcriptional corepressor carboxyl-terminal binding protein 1
(CtBP1, Lin et al., 2003), and DHHC domain palmitoyl acetyl
transferases such as ZDHHC23/NIDD (Saitoh et al., 2004).
Therefore, the ability of NOS1AP to occlude the nNOS PDZ-
binding pocket, the requirement of the NOS1AP ExF motif
and additional structural element in this occlusion and the
possible pharmacological manipulation or even endogenous
regulation of these determinants would be expected to determine
whether nNOS is competent to recruit these additional candidate
interacting proteins. This in turn could reshape nNOS-dependent
signaling profiles and thus influence disease mechanisms
involving nNOS.
CONCLUSION
Our findings extend our understanding of nNOS-NOS1AP
interaction by revealing the contribution of three separate
elements. In addition to (i) the recently described internal
NOS1AP-ExF motif region which is sufficient for interaction
(Li et al., 2015), and (ii) the initially described NOS1AP-
PDZ ligand which is not sufficient alone but increases stability
and affinity in the presence of the ExF motif (Jaffrey et al.,
1998; Li et al., 2015), we provide evidence here for (iii) a
third NOS1AP element, the structure and therefore function
of which is sensitive to denaturation, that orients the other
two NOS1AP elements to allow them to form a stable
interaction with nNOS and occlude alternate ligands from
the nNOS ligand binding pocket. It would be important to
determine if this third element is merely encoded in a robust
and static manner by the amino acid sequence of NOS1AP
or whether it is dynamically regulated by cellular signaling
pathways and whether it is amenable to pharmacological
modulation. Our findings therefore have implications for drug
discovery opportunities for the numerous diseases that have
been linked to nNOS and NOS1AP as well as the manner
in which the small molecule inhibitor compounds for the
different sites could be identified. It is important to consider
that NOS1AP has been reported to mediate the activation of
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p38MAPK (Li et al., 2013, 2015), a kinase which is in turn
linked to excitotoxicity (Cao et al., 2004, 2005; Semenova et al.,
2007), neurodegeneration (Dau et al., 2014; Ittner et al., 2014;
Roy et al., 2015), neuropsychiatric conditions (Bruchas et al.,
2011; Ehrich et al., 2015) and neuropathic pain (Berta et al.,
2016). As the neurological side effects of direct p38MAPK
inhibitors have been addressed in clinical trials by reducing brain
penetrance (Krementsov et al., 2013), inhibiting p38MAPK in
the CNS may be difficult. Targeting disease-related upstream
mechanisms such as NOS1AP could in this case be an attractive
alternative approach. Moreover, as NOS1AP has itself been
directly associated with a range of disorders and diseases, it would
be valuable to develop mathematical models to describe and
predict its function and regulation under different conditions. As
more details emerge of the regulatory mechanisms of NOS1AP,
such as those we present here, a model to predict the interaction
of NOS1AP with its targets and the impact of inhibitors at specific
sites on these interaction surfaces becomes increasingly feasible.
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